Saponin (Saponin)

Saponins are a diverse class of triterpene or steroidal glycoside compounds found in numerous plant species, not a single nutrient but a broad category of bioactive phytochemicals. Key subclasses and sources include: Steroidal saponins (e.g., dioscin from Dioscorea spp., ~0.5–3% dry weight; protodioscin from Tribulus terrestris, ~0.1–0.8% dry weight; timosaponins from Anemarrhena asphodeloides), Triterpene saponins (e.g., ginsenosides Rg1, Rb1, Rd from Panax ginseng/notoginseng, ~2–8% of dried root; astragalosides from Astragalus membranaceus, ~0.02–0.06%; soyasaponins from soybean, ~0.1–0.5% of seed; glycyrrhizin from licorice root, ~2–14% dry weight; quillaja saponins from Quillaja saponaria bark, ~8–14%). Panax notoginseng saponins (PNS) referenced in clinical data primarily contain notoginsenoside R1, ginsenoside Rg1, ginsenoside Rb1, ginsenoside Rd, and ginsenoside Re as major components; typical PNS standardized extracts contain ≥75–85% total saponins. Panax quinquefolius saponins (PQS) are enriched in protopanaxadiol-type ginsenosides (Rb1, Rb2, Rc, Rd). Saponins are amphiphilic molecules with a hydrophobic aglycone (sapogenin) linked to one or more sugar chains (glucose, galactose, rhamnose, xylose, arabinose, glucuronic acid). They contain no significant macronutrients (protein, fat, carbohydrate), vitamins, or minerals of nutritional relevance themselves. Bioavailability notes: Oral bioavailability of intact saponins is generally very low (often <5%) due to large molecular weight (600–1800 Da), hydrophilicity of sugar moieties, poor membrane permeability, and extensive gut microbial metabolism. Ginsenoside Rb1 oral bioavailability is estimated at ~1–4%; Rg1 at ~2–7%. Gut microbiota deglycosylate saponins into more bioavailable metabolites (e.g., ginsenoside Rb1 → compound K; Rg1 → protopanaxatriol), which are considered the primary active forms in systemic circulation. Peak plasma concentrations typically reached 4–8 hours post-oral dosing. Co-administration with lipids or formulation in nanoparticles/liposomes can enhance absorption 2–5 fold. Saponins themselves can enhance absorption of co-administered compounds by increasing intestinal membrane permeability and inhibiting P-glycoprotein efflux. Clinical dosing in referenced studies: PNS typically administered at 100–450 mg/day IV or 200–600 mg/day orally; PQS at 300–1200 mg/day orally.